Aclarion, Inc. (ACONW) stock
ACONWNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as ACON
$0.02+0.00 (0.00%)
Close on Oct 30, 2026Market cap $5.62MP/E –Yield –
Aclarion gross margin
Gross margin is gross profit as a percentage of revenue.
Aclarion's gross margin for the twelve months ending Jun 30, 2026 was 21.8%. For fiscal 2025 it was 9.0%, against -85.2% the year before. The highest annual figure on record is 9.0% in fiscal 2025.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.0% | +94.2 |
| FY2024 | Dec 31, 2024 | -85.2% | −84.7 |
| FY2023 | Dec 31, 2023 | -0.4% | +7.6 |
| FY2022 | Dec 31, 2022 | -8.0% | +6.7 |
| FY2021 | Dec 31, 2021 | -14.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 32.9% | +6.3 |
| Q1 FY2026 | Mar 31, 2026 | 17.7% | +41.4 |
| Q4 FY2025 | Dec 31, 2025 | 9.7% | +110.6 |
| Q3 FY2025 | Sep 30, 2025 | 23.2% | +71.2 |
| Q2 FY2025 | Jun 30, 2025 | 26.6% | +138.9 |
| Q1 FY2025 | Mar 31, 2025 | -23.6% | +68.9 |
| Q4 FY2024 | Dec 31, 2024 | -100.9% | −60.2 |
| Q3 FY2024 | Sep 30, 2024 | -48.1% | −45.5 |
| Q2 FY2024 | Jun 30, 2024 | -112.3% | −99.3 |
| Q1 FY2024 | Mar 31, 2024 | -92.6% | −124.0 |
| Q4 FY2023 | Dec 31, 2023 | -40.7% | −64.0 |
| Q3 FY2023 | Sep 30, 2023 | -2.6% | −9.1 |
| Q2 FY2023 | Jun 30, 2023 | -13.1% | +22.4 |
| Q1 FY2023 | Mar 31, 2023 | 31.5% | +79.5 |
| Q4 FY2022 | Dec 31, 2022 | 23.2% | +2.5 |
| Q3 FY2022 | Sep 30, 2022 | 6.6% | +46.6 |
| Q4 FY2021 | Dec 31, 2021 | -35.4% | – |
| Q3 FY2021 | Sep 30, 2021 | -48.1% | – |
| Q2 FY2021 | Jun 30, 2021 | 20.7% | – |
| Q1 FY2021 | Mar 31, 2021 | -40.0% | – |